INTRODUCTION
Serum thyroglobulin is the primary biochemical tumor-marker used to monitor differentiated thyroid cancer (DTC) [1, 2, 3 && ]. A global rise in the prevalence of DTC [4,5 & ,6 ] is increasing the number of thyroidectomized patients needing lifelong monitoring for persistent or recurrent disease, typically involving periodic (6-12 months) serum thyroglobulin measurements augmented by anatomic imaging, as appropriate for recurrence risk. For decades, standard DTC treatment has involved total thyroidectomy followed by one or more doses of radioiodine (RAI) before long-term thyroid hormone suppression of thyroid-stimulating hormone (TSH), without regard to recurrence risk [1, 2, 7, 8] . Yet most thyroid tumors are small ( 1.0 cm), belong to the papillary histotype (PTC) and have a low recurrence risk even when treated by surgery alone [9] [10] [11] . Increasingly, a more individualized, riskstratified, approach to DTC diagnosis and management is being adopted [5 & ,7,8,12] that limits RAI treatment to high-risk DTC (the minority of patients) [13,14 & ,15] . As a consequence, more sensitive (second-generation) thyroglobulin immunometric assay (Tg 2G IMA) measurements, which have an order of magnitude higher functional sensitivity ( 0.10 mg/l) than older (first-generation) tests (functional sensitivity $1.0 mg/l), are rapidly becoming the standard of care [3 && ,16 && ]. Over recent years, it has become clear that thyroglobulin assays need second-generation functional sensitivity in order to monitor the low basal (non-TSH stimulated) thyroglobulin concentrations arising from the intact surgical remnant of low-risk DTC patients who no longer receive routine RAI remnant ablation. Also that a basal Tg 2G IMA below 0.20 mg/l has comparable negative predictive value to a recombinant human TSH (rhTSH)-stimulated thyroglobulin below the consensus cutoff of 2.0 mg/l [3 && ,17-20] . Further, as with other biochemical tumor-marker tests such as calcitonin and carcinoembryonic antigen, the basal Tg 2G IMA trend and doubling time (measured using the same thyroglobulin method, preferably in the same laboratory) have been shown to be important prognostic parameters [21] [22] [23] [24] [25] 26 & ].
The primary limitation of Tg 2G IMA measurement is its high propensity for interference from both thyroglobulin autoantibodies (TgAb) [27] [28] [29] 30 && ] and heterophile antibodies, primarily human antimouse antibodies (HAMA) [31] [32] [33] . This review will focus on technical issues relating to current thyroglobulin methodology that impact the clinical utility of thyroglobulin testing and discuss how paradigms for postoperative DTC monitoring differ depending on the TgAb status of the patient.
REVIEW OF FOUR DECADES OF THYROGLOBULIN METHODOLOGY
During the last four decades, thyroglobulin has been measured by three different classes of methodology [34] ]. These classes of thyroglobulin method differ fundamentally in functional sensitivity potential and propensity for interference from HAMA and TgAb [34] .
Most thyroglobulin testing is made using IMA methods that can display ten-fold differences in functional sensitivity. A generational nomenclature system, similar to that used for TSH assays, has been adopted to distinguish between different assays because assay functional sensitivity is such a critical determinant of the clinical utility of thyroglobulin testing [ 
TECHNICAL LIMITATIONS OF THYROGLOBULIN METHODOLOGY
Three principle technical limitations currently negatively impact the clinical utility of thyroglobulin methods: first, suboptimal functional sensitivity; second, between-method discordances and third, interferences, primarily from TgAb, but also heterophilic antibodies, the most common being HAMA.
Functional sensitivity
Manufacturers and laboratories are unsure which parameter best describes a thyroglobulin assay's detection limit [34] . Immunoassay precision profiles are typically U-shaped, with low range precision and matrix bias determining the reliability for detecting low analyte concentrations [46, 57] . This low range precision erodes as measurements are made over longer periods of time as a consequence of changes in reagent lots and calibrators, instrumentation factors and other intangible variables [58] . This deterioration in precision is particularly problematic for serial thyroglobulin measurements because postoperative DTC monitoring necessitates monitoring low thyroglobulin concentrations across long clinical intervals (6-12 months) between determinations. Functional sensitivity is the only parameter that represents the imprecision of low-range thyroglobulin measurement made under conditions representative of clinical practice. Specifically, functional sensitivity is defined as 'the thyroglobulin concentration that can be measured in human serum with 20% between-run coefficient of variation over a 6-12 months period, during which time more than two reagent lots and more than two instrument calibrations should be used' [3 && ,34,44] . Functional sensitivity contrasts with the limit of quantitation calculation favored by many manufacturers and laboratories that is defined by the 20% coefficient of variation of runs made over short periods of time (days or weeks) without stipulations regarding the use of the clinically relevant matrix (human serum) or capturing any lot-to-lot variability [34] . It should be noted that because both thyroglobulin and TgAb are measured concurrently, the protocol for determining the functional sensitivity of thyroglobulin and TgAb assays is the same [44] .
Between-method discordances
Restandardization against the Certified Reference Material, CRM-457, has greatly reduced differences between thyroglobulin assays over the last decade [59] [60] [61] . However, despite universal adoption of this standard, different methods can display a two-fold difference in the numeric thyroglobulin values reported for the same serum [29, 45, 46, 57, 62, 63] . This is evident in Fig. 1 showing UK National External Quality Assessment Service for Thyroglobulin surveys for four TgAb-negative sera (A-D) that had thyroglobulin measured by each of 51 laboratories using 10 different methods. Thyroglobulin molecular heterogeneity is the likely cause of this method variability. Thyroglobulin is a large (660 kDa) dimeric glycoprotein that is heterogeneous with respect to differential thyroglobulin mRNA splicing, glycosylation and degree of iodination, also, the processes involved in thyroglobulin maturation, dimerization and molecular folding are complex and may become dysregulated in tumor tissue [64] . Given the conformational nature of thyroglobulin epitopes [65, 66] , it is not surprising that different immunoassays, employing different thyroglobulin antibody reagents, detect serum thyroglobulin isoforms with variable potency. The severe between-method discordances seen for tumor-derived thyroglobulins are reflected in abnormal ratios between the values reported by different methods that suggest different epitopes may be masked or exposed when the thyroglobulin structure is abnormal [62] . The magnitude of the between-method variability seen in Fig. 1 far exceeds the expected within-person thyroglobulin variability that approximates 15% [67] . In clinical practice, these between-method biases necessitate that postoperative thyroglobulin monitoring be made using the same manufacturers method and preferably the same laboratory [ 
FACTORS INFLUENCING SERUM THYROGLOBULIN CONCENTRATIONS
Because the source of thyroglobulin protein is thyroid tissue-specific and not tumor-specific, a number of factors will influence the interpretation of serum thyroglobulin concentrations [44] . These factors include the following: first, the mass of thyroid tissue present (normal thyroid remnant plus any tumor); second, the tissue's efficiency or inefficiency for thyroglobulin secretion; third, injury secondary to surgery, fine-needle aspiration biopsy, or RAI therapy can cause thyroglobulin release from damaged tissue that elevates serum thyroglobulin concentrations; fourth, the degree and chronicity of TSH stimulation that has a profound effect on serum thyroglobulin and fifth, the possibility of increased metabolic clearance of thyroglobulin-TgAb complexes that would alter the interpretation of the serum thyroglobulin concentrations in the presence of TgAb [80] [81] [82] [83] .
POSTOPERATIVE SERUM THYROGLOBULIN MONITORING
Serum thyroglobulin measurement only becomes a reliable tumor-marker after total thyroidectomy. Preoperative thyroglobulin measurement is considered to have limited value, although a number of studies report that an elevated preoperative serum thyroglobulin is a risk factor for nodular malignancy [84] [85] [86] [87] . In addition, the relationship between the preoperative serum thyroglobulin and tumor burden may give some indication of the tumor's efficiency for thyroglobulin secretion and set a threshold for determining the significance of postoperative serum thyroglobulin changes [2] . Preoperative TgAb measurement may also have clinical utility. One report found nodular malignancy more likely when TgAb, but not thyroid peroxidase antibodies, were detected [88] . Most DTC patients with circulating TgAb have evidence of thyroid autoimmunity [66, 89, 90] ,49]. Although the low frequency of DTC recurrences impacts the ability to study positive predictive values (PPVs) [45] , the PPV of an rhTSH-stimulated thyroglobulin above 1 to 2 mg/l appears comparable to a basal Tg 2G IMA above 0.10-0.20 mg/l [20, 49, 101] . By considering the principle factors influencing serum thyroglobulin concentrations (thyroid tissue mass, injury and TSH), it is evident that the trend in basal Tg 2G IMA, measured when TSH is suppressed, should reflect changes in thyroid tissue mass and thus provide a more sensitive parameter for disease than rhTSH-stimulated thyroglobulin testing. This is supported by a growing number of studies showing the prognostic utility of monitoring the basal Tg 2G IMA trend and thyroglobulin doubling time [22, 25, 102] , as is customary for other tumor-marker such as carcinoembryonic antigen and calcitonin [21] .
The clinical utility of monitoring Tg 2G IMA trends is illustrated in Figs 2 and 3 . Figure 2 shows postoperative serum Tg 2G IMA monitoring (TSH < 0.10 mIU/l at all points) of 18, non-RAI treated, TgAb-negative, PTC patients who displayed no evidence of disease at the end of more than 5 years follow-up. As previously reported, serum Tg 2G IMA fell to a nadir of less than 0.05 to 0.5 mg/l during the first postoperative year (Fig. 2a) -the same thyroglobulin range as seen following thyroidectomy for medullary carcinoma [103] and consistent with the thyroglobulin secretion expected from the approximately 1 g of normal thyroid remnant remaining after thyroidectomy [53 && ,104-106] . It should be noted that at a median of 0.17 postoperative years, serum Tg 2G IMA was below 0.10 mg/l in 12 out of 18 (67%) cases, and even below the functional sensitivity limit of 0.05 mg/l in three out of 18 (17%) cases, affirming that without RAI treatment the normal thyroid remnant typically secretes a very low thyroglobulin level in the face of TSH suppression [53 && ,104,105] . Figure 2b shows that serum Tg 2G IMA values remain remarkably constant in the less than 0.05-0.5 mg/l range when TSH suppression is maintained during long-term follow-up. In fact, the median within-person percentage coefficient of variation of serum Tg 2G IMA measurements made throughout 2-15 years of postoperative monitoring approximated 30%, illustrating the consistency of thyroglobulin secretion from normal thyroid remnant tissue. It is this consistency of remnant secretion that is why the basal Tg 2G IMA doubling time (measured at a constant TSH level) is a sensitive parameter for detecting recurrence [22, 25, 102] . Figure 3 shows 25 years of postoperative Tg 2G IMA monitoring (Beckman Access Tg 2G IMA measurement of frozen archived specimens [37 && ]) of a TgAb-negative PTC patient with persistent and recurrent disease. This case illustrates a number of points which are as follows: first, the high preoperative thyroglobulin (154 mg/L) suggested that serum thyroglobulin would be a sensitive postoperative tumor-marker; second, the $ten-fold thyroglobulin stimulation in response to thyroid hormone withdrawal prior to RAI suggested the tumor was responsive to TSH and supported the efficacy for TSH suppression; third, surgery was clearly a more effective treatment for metastatic PTC lymph nodes than RAI treatments; fourth, combined imaging modalities were needed to detect disease; fifth, persistent disease remained quiescent during TSH suppression for many years before an active recurrence manifested; sixth, a rising trend in basal Tg 2G IMA (measured at constant TSH) suggested an increase in tumor mass because thyroglobulin secretion from normal remnant tissue (Fig. 2) remains constant. It was also likely that this patient had little or no normal remnant left after two doses of RAI and seventh, the doubling of basal Tg 2G IMA during TSH suppression approximated 4 years -an interval indicating a good, long-term prognosis [22] .
Optimal monitoring of patients with thyroglobulin autoantibody
A recent review of 1500 consecutive DTC patients with more than 2 years postoperative follow-up found that although 22.7% were currently TgAbpositive, an additional 12.7% had a past history of TgAb-positivity but had become TgAb-negative during the postoperative period [27,37 [27,37 && ,98,99], the persistence of TgAb, a rising TgAb trend, the failure of TgAb to fall or a de-novo TgAb appearance is highly suspicious for active disease [7,14 & 
,37
&& ,89,92,100,107]. However, a rising TgAb concentration is not specific for recurrence but can also result from any thyroid injury causing thyroglobulin release (RAI treatment, lymph node biopsy or additional surgery) [90] . It is now apparent that TgAb concentrations respond to changes in the mass of thyroglobulin-secreting thyroid tissue so that the trend in TgAb concentrations can be used as a surrogate tumor-marker [7, . Despite a negative diagnostic whole body scan (DxWBS), the elevated thyroglobulin prompted a second RAI treatment (150 mCi) that revealed foci of thyroid uptake and a submandibular lymph node on the post-treatment scan. However, the two RAI treatments had little effect on the elevated serum thyroglobulin, which remained persistently elevated for 5 years prompting computed tomography scans of the neck and chest (negative) followed by a PET scan that revealed a lymph node, confirmed by FNA as positive for PTC. During a left jugular dissection (surgeries indicated by red crosses), a 1.5 cm lymph node metastasis was removed producing a significant fall in serum Tg 2G IMA into the 0. Fig. 4 , in which serum TgAb monitoring of four PTC patients without disease is shown in the upper panels, to contrast with four PTC patients with persistent or Figure 4b shows these data converted to percentage of the initial value. Disease-free patients may have a transient early TgAb rise in response to thyroglobulin released by surgical injury or RAI treatment (solid arrows), but thereafter TgAb values typically decline over time (years) to less than 10% of initial level. These disease-free patients were selected to have different initial TgAb concentrations to illustrate that declining TgAb concentrations do not necessarily become undetectable during follow-up, unless the initial TgAb was low. Figures 4c and 4d show comparative data for four PTC patients with persistent or recurrent disease detected during follow-up (indicated by yellow crosses). A de-novo TgAb appearance, a TgAb rise or a stable TgAb concentration that fails to fall below 10% of initial value are indications of active disease. DTC, differentiated thyroid cancer; LN, lymph node metastases; PTC, papillary histotype; RAI, radioiodine; TgAb, thyroglobulin autoantibody; Tx., thyroidectomy.
recurrent disease shown in the lower panels. Figure 4a shows that TgAb-positive patients rendered disease-free by thyroidectomy may display a transient early rise in TgAb in response to the thyroglobulin released by the surgery and/or RAI treatment, but thereafter TgAb progressively declines and may become undetectable during the early years of follow-up, especially if the initial TgAb concentration was low. Disease-free patients with high TgAb concentrations typically display a slow progressive TgAb decline over years but may not achieve full TgAb-negativity, possibly because of the long-lived memory of plasma cells [108] . The left-hand panels show the TgAb concentrations expressed as percentage of an initial (0-3 month) value. Figure 4b shows that when patients are disease-free, TgAb concentrations typically fall by more than 50% during the first postoperative year [26 & ,30
&& ,34,100] and thereafter continue to fall to less than 10% of initial value over subsequent years. These TgAb trends contrast with those of the PTC patients with persistent or recurrent disease shown in the lower panels. Figure 4c shows that when there is active disease, TgAb concentrations may show a decline in the early months following thyroidectomy that is not sustained, or may be followed by a progressive TgAb rise or even a de-novo TgAb appearance sometimes years after TgAb absence, necessitating concurrent TgAb measurement with every thyroglobulin test [30 && ,44,107] . Figure 4d illustrates that although some patients with active disease have a 50% TgAb decline in the first postoperative year, TgAb rarely declines to less than 10% unless the disease is successfully treated.
CONCLUSION
Now that RAI treatment is no longer considered necessary to treat low-risk DTC, postoperative serum thyroglobulin monitoring will primarily be made for disease-free patients who have functioning thyroid remnants that typically give rise to serum basal Tg 2G IMA concentrations in the 0.05-0.5 mg/l or less range when TSH is suppressed. When TgAb is absent ($75% of DTC), the serum basal Tg 2G IMA trend and doubling time are important prognostic parameters. However, when TgAb is present, Tg 2G IMA measurement is unreliable because of interference causing Tg 2G IMA underestimation and the trend in TgAb concentrations (measured by the same method) becomes the primary (surrogate) tumor-marker.
